Latest Breaking News On - Calgary cumming school - Page 9 : comparemela.com
Cancer-detecting cyclotron announced for Calgary
calgary.ctvnews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from calgary.ctvnews.ca Daily Mail and Mail on Sunday newspapers.
To Master Stroke Thrombectomy, It Takes Way More Than 50 Cases
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Gregory Kline, MD, on the Role of Frequent Bone Mineral Density Testing After Menopause
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
The Newly Institute Announces Its Medical and Corporate Advisory Boards
The Newly Institute s world class advisory boards will drive innovation in revolutionizing mental health treatment and delivery.
The Medical Advisory Board is comprised of psychiatrists and physicians who are leaders in ketamine and depression, trauma, anxiety, pain, addiction, toxicology.
The Corporate Advisory Board consists of decorated veterans, first responders, psychotherapists, disability specialists, and First Nations advocates.
Calgary, Alberta (Newsfile Corp. - April 30, 2021) - Aspen Island Therapeutics Inc. DBA The Newly Institute (
The Newly or the
Company ), an Alberta-based corporation on track to become Canada s largest and premier operator of psychedelic assisted psychotherapy clinics, is pleased to announce its medical and corporate advisory boards.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of .
Arch BiopartnersFebruary 26, 2021 GMT
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.